Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;25(3):416-22.
doi: 10.1097/IGC.0000000000000361.

Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer

Ivana Rizzuto  1 , Chara Stavraka, Jayanta Chatterjee, Jane Borley, Thomas Glass Hopkins, Hani Gabra, Sadaf Ghaem-Maghami, Les Huson, Sarah P Blagden
Affiliations

Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer

Ivana Rizzuto et al. Int J Gynecol Cancer. 2015 Mar.

Abstract

Objective: The aim of this study was to construct a prognostic index that predicts risk of relapse in women who have completed first-line treatment for ovarian cancer (OC).

Methods: A database of OC cases from 2000 to 2010 was interrogated for International Federation of Gynecology and Obstetrics stage, grade and histological subtype of cancer, preoperative and posttreatment CA-125 level, presence or absence of residual disease after cytoreductive surgery and on postchemotherapy computed tomography scan, and time to progression and death. The strongest predictors of relapse were included into an algorithm, the Risk of Ovarian Cancer Relapse (ROVAR) score.

Results: Three hundred fifty-four cases of OC were analyzed to generate the ROVAR score. Factors selected were preoperative serum CA-125, International Federation of Gynecology and Obstetrics stage and grade of cancer, and presence of residual disease at posttreatment computed tomography scan. In the validation data set, the ROVAR score had a sensitivity and specificity of 94% and 61%, respectively. The concordance index for the validation data set was 0.91 (95% confidence interval, 0.85-0.96). The score allows patient stratification into low (<0.33), intermediate (0.34-0.67), and high (>0.67) probability of relapse.

Conclusions: The ROVAR score stratifies patients according to their risk of relapse following first-line treatment for OC. This can broadly facilitate the appropriate tailoring of posttreatment care and support.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Examples of the ROVAR score.
See this image and copyright information in PMC

References

    1. Office for National Statistics [on request], June 2012. http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations–engl.... Accessed May 1, 2014.
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics. Ca Cancer J Clin. 2013; 63: 11– 30. - PubMed
    1. on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 (suppl 6): vi24– vi32. - PubMed
    1. Nama V, Nordin A, Bryant A. Patient-reported outcome measures for follow-up after gynaecological cancer treatment. Cochrane Database Syst Rev. 2013;( 11): CD010299. - PMC - PubMed
    1. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3194– 3200. - PubMed

Publication types

MeSH terms